Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Xeris Biopharma Holdings, Inc. (XERS)

Xeris raises 2026 revenue guidance to $395 million-$405 million after 44% Q3 growth

Positive Impact 4 of 5 guidance Written later

Xeris reported third quarter 2026 total revenue of $107.2 million, up 44% from a year earlier, with Recorlev net revenue up 93% to $71.5 million. The company raised its full-year 2026 total revenue guidance to $395 million-$405 million and its 2030 total revenue outlook to more than $1 billion, up from approximately $750 million. Shareholders also face a nine-month net loss of $17.6 million, driven by a one-time non-cash charge of about $30.8 million tied to the 2028 Convertible Notes exchange agreements.

Key points

  • Q3 2026 total revenue was $107.2 million, up 44% from $74.4 million; Recorlev net revenue was $71.5 million, up 93%.
  • Q3 2026 net income was $11.3 million, or $0.06 per diluted share, compared with $0.6 million a year earlier.
  • Full-year 2026 total revenue guidance raised to $395 million-$405 million.
  • Nine-month 2026 net loss was $17.6 million, including a one-time non-cash charge of about $30.8 million in the second quarter.

The filing

CompanyXeris Biopharma Holdings, Inc. (XERS)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:12 AM ET
Accession number0001867096-26-000114

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.